Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566130 | 0.84 | DAO (0.43) | DAO | |
| SCHEMBL5419898 | 0.81 | DAO (0.53) | GAADAO | |
| SCHEMBL4346481 | 0.74 | DPYD (0.45) | GAA | |
| SCHEMBL4344338 | 0.74 | DPYD (0.45) | GAA | |
| SCHEMBL28417137 | 0.72 | GAA (0.46) | GAA | |
| SCHEMBL4353311 | 0.71 | DPYD (0.50) | GAA | |
| SCHEMBL4495952 | 0.71 | ATAD2 (0.47) | GAA | |
| SCHEMBL4519523 | 0.70 | KMT2A (0.42) | — | |
| SCHEMBL4356407 | 0.68 | ATAD2 (0.44) | — | |
| SCHEMBL44459 | 0.68 | GAA (0.52) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101883-B2 | Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20030229081-A1 | Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229081-A1 | Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases | UNG, IDUA, TNF | GAA 33/4885DAO 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.